KEGG   DRUG: Vudalimab
Entry
D12186                      Drug                                   
Name
Vudalimab (USAN)
Formula
C5593H8590N1492O1726S34
Exact mass
125360.0765
Mol weight
125437.2205
Sequence
(Chain A)
EIVLTQSPAT LSASPGERVT LTCRASQSVG NDVAWYQQKP GQAPRLLINY ASHRYTGVPD
RFTGSGYGTE FTLTISSVQS EDFGVYYCQQ DFSSPRTFGG GTKVEIKGKP GSGKPGSGKP
GSGKPGSEVQ LVESGGGLVK PGGSLRLSCV ASGFTFSNYW MNWVRQAPGK GLEWVAEIRL
YSNNYATHYA ESVKGRFTIS RDDSKSTLYL QMNNLKTEDT GVYYCTRYYG NYGGYFDVWG
RGTLVTVSSE PKSSDKTHTC PPCPAPPVAG PSVFLFPPKP KDTLMISRTP EVTCVVVDVK
HEDPEVKFNW YVDGVEVHNA KTKPREEQYN STYRVVSVLT VLHQDWLNGK EYKCKVSNKA
LPAPIEKTIS KAKGQPREPQ VYTLPPSREQ MTKNQVKLTC LVKGFYPSDI AVEWESNGQP
ENNYKTTPPV LDSDGSFFLY SKLTVDKSRW QQGNVFSCSV LHEALHSHYT QKSLSLSPGK
(Chain B)
EVQLVESGGG LVKPGGSLRL SCAASGFTFS SYTMHWVRQA PGKGLEWVSF ISYDGNNKYY
ADSVKGRFTI SRDNAKNSLY LQMNSLRAED TAVYYCARTG WLGPFDYWGQ GTLVTVSSAS
TKGPSVFPLA PSSKSTSGGT AALGCLVKDY FPEPVTVSWN SGALTSGVHT FPAVLQSSGL
YSLSSVVTVP SSSLGTQTYI CNVNHKPSDT KVDKKVEPKS CDKTHTCPPC PAPPVAGPSV
FLFPPKPKDT LMISRTPEVT CVVVDVKHED PEVKFNWYVD GVEVHNAKTK PREEEYNSTY
RVVSVLTVLH QDWLNGKEYK CKVSNKALPA PIEKTISKAK GQPREPQVYT LPPSREEMTK
NQVSLTCDVS GFYPSDIAVE WESDGQPENN YKTTPPVLDS DGSFFLYSKL TVDKSRWEQG
DVFSCSVLHE ALHSHYTQKS LSLSPGK
(Chain C)
EIVLTQSPGT LSLSPGERAT LSCRASQSVS SSYLAWYQQK PGQAPRLLIY GAFSRATGIP
DRFSGSGSGT DFTLTISRLE PEDFAVYYCQ QYGSSPWTFG QGTKVEIKRT VAAPSVFIFP
PSDEQLKSGT ASVVCLLNNF YPREAKVQWK VDNALQSGNS QESVTEQDSK DSTYSLSSTL
TLSKADYEKH KVYACEVTHQ GLSSPVTKSF NRGEC
(Disulfide bridge: A23-A88, A149-A225, A260-B227, A263-B230, A294-A354, A400-A458, B22-B96, B145-B201, B221-C215B261-B321, B367-B425, C23-C89, C135-C195)
  Type
Peptide
Class
Antineoplastic
 DG02938  Immune checkpoint inhibitor
Efficacy
Antineoplastic, Immunomodulator, Immune checkpoint inhibitor
Comment
Monoclonal antibody; bispecific antibody
Chain A: anti-PDCD1, Chain B: anti-CTLA4
Target
PDCD1 (PD1, CD279) [HSA:5133] [KO:K06744]
CTLA4 (CD152) [HSA:1493] [KO:K06538]
  Pathway
hsa04514  Cell adhesion molecules
hsa04660  T cell receptor signaling pathway
Brite
Drug groups [BR:br08330]
 Antineoplastic
  DG02938  Immune checkpoint inhibitor
   D12186  Vudalimab
Target-based classification of drugs [BR:br08310]
 Cell surface molecules and ligands
  Other cell surface molecules
   Immune checkpoints
    CTLA4 (CD152)
     D12186  Vudalimab (USAN)
    PDCD1 (PD1, CD279)
     D12186  Vudalimab (USAN)
Other DBs
CAS: 2329669-72-7
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system